Home/Filings/4/0001209191-14-050674
4//SEC Filing

IDENIX PHARMACEUTICALS INC 4

Accession 0001209191-14-050674

CIK 0001093649operating

Filed

Aug 4, 8:00 PM ET

Accepted

Aug 5, 5:37 PM ET

Size

5.6 KB

Accession

0001209191-14-050674

Insider Transaction Report

Form 4
Period: 2014-08-05
Dumas Jacques
EVP, Chief Scientific Officer
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2014-08-05250,0000 total
    Exercise: $7.42Exp: 2024-01-19Common Stock (250,000 underlying)
Footnotes (1)
  • [F1]These options, which vested in 48 equal monthly installments beginning on January 31, 2014, were cancelled pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co. Inc. in exchange for a cash payment of $17.08 per share, representing the difference between the exercise price of the options and $24.50 per share.

Issuer

IDENIX PHARMACEUTICALS INC

CIK 0001093649

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001093649

Filing Metadata

Form type
4
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 5:37 PM ET
Size
5.6 KB